Search Results

NIH-12848 5 mg  | 99.84%

TargetMol

NIH-12848 is a putative inhibitor of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) with an IC50 of 1 μM.

More Information Supplier Page

NIH-12848 50 mg  | 99.84%

TargetMol

NIH-12848 is a putative inhibitor of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) with an IC50 of 1 μM.

More Information Supplier Page

NIH-12848 25 mg  | 99.84%

TargetMol

NIH-12848 is a putative inhibitor of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) with an IC50 of 1 μM.

More Information Supplier Page

NIH-12848 10 mg  | 99.84%

TargetMol

NIH-12848 is a putative inhibitor of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) with an IC50 of 1 μM.

More Information Supplier Page

NIH-12848 100 mg  | 99.84%

TargetMol

NIH-12848 is a putative inhibitor of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) with an IC50 of 1 μM.

More Information Supplier Page

E4CPG 5 mg  | 99.96%

TargetMol

E4CPG is a novel group I/II metabotropic glutamate receptor antagonist, more potent than (RS)-MCPG.

More Information Supplier Page

E4CPG 50 mg  | 99.96%

TargetMol

E4CPG is a novel group I/II metabotropic glutamate receptor antagonist, more potent than (RS)-MCPG.

More Information Supplier Page

E4CPG 25 mg  | 99.96%

TargetMol

E4CPG is a novel group I/II metabotropic glutamate receptor antagonist, more potent than (RS)-MCPG.

More Information Supplier Page

E4CPG 10 mg  | 99.96%

TargetMol

E4CPG is a novel group I/II metabotropic glutamate receptor antagonist, more potent than (RS)-MCPG.

More Information Supplier Page